NEW YORK (GenomeWeb News) – UK-based Asterand today said that it will acquire BioSeek, a developer of cell-based assay systems, in a deal worth up to $14 million.

Asterand, which provides tissue-based services for drug discovery, said that the acquisition will provide it with highly complementary technologies, specifically BioSeek's BioMap platform and human cell-based assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.